A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age

Inclusion Criteria:

• The participant has a clinical history of recurrent headache consistent with thediagnosis of migraine for at least 6 months before screening, consistent with ICHD-3criteria (Headache Classification Committee of the IHS 2013), and a history of ≤=14headache days per month in each of the 3 months prior to screening (visit 1).

• The participant or parent/caregiver maintain a prospectively collected headachediary

• The participant does not have chronic daily headache. For the purposes of thisstudy, chronic daily headache is operationally defined as <4 headache-free daysduring the 28-day baseline period.

NOTE: Additional criteria apply; please contact the investigator for more information.

Exclusion Criteria:

• The participant is using medications containing opioids (including codeine) orbarbiturates (including Fiorinal®, Fioricet®, or any other combination containingbutalbital) for the treatment of migraine during the 3 months prior to the day ofthe screening visit.

• The participant or parent/caregiver maintain a prospectively collected headachediary

• The participant has used an intervention/device (eg, scheduled nerve block ortranscranial magnetic stimulation) for the treatment of migraine or in the head orneck area for any condition during the 2 months prior to the day of the screeningvisit.

• The participant has a current history of a clinically significant psychiatriccondition, at the discretion of the investigator. Any prior history of a suicideattempt, or a history of suicidal ideation with a specific plan within the past 2years, must be excluded.

• The participant has an ongoing infection or a known history of humanimmunodeficiency virus infection, tuberculosis, Lyme disease, or chronic hepatitis Bor C, or a known active infection of coronavirus disease 2019 (COVID-19).

• The participant has a past or current history of cancer.

• The participant is pregnant or nursing.

• The participant has a history of hypersensitivity reactions to injected proteins,including mAbs, or a history of Stevens-Johnson Syndrome or toxic epidermalnecrolysis syndrome, or the participant is concomitantly using lamotrigine.

• The participant received a live attenuated vaccine (eg, intranasal flu vaccine, andmeasles, mumps, and rubella vaccine) within the 12-week period prior to screening.Note: If a medical need arises during the study, the participant may receive a liveattenuated vaccine.

• The participant has a current or past medical history of hemiplegic migraine.

NOTE: Additional criteria apply; please contact the investigator for more information.